Navigation Links
Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
Date:1/5/2017

LA JOLLA, Calif., Jan. 4, 2017 /PRNewswire/ -- Avidity Biosciences LLC, a biotechnology company advancing Antibody-siRNA Conjugates (ASCs) as a new class of precision medicines, today announced a publication entitled, "Targeting Therapeutic Oligonucleotides," in the January 5, 2017 issue of the New England Journal of Medicine.1 The publication, authored by Arthur A. Levin, Ph.D., executive vice president of research and development, appears in the Clinical Implications of Basic Research section.

In the publication, Dr. Levin summarizes the advantages of targeted strategies for the delivery of therapeutic oligonucleotides. 

"Recent work indicates that the usefulness of therapeutic oligonucleotides can be increased by conjugating oligonucleotides with targeting moieties so that they home to specific cell types," said Dr. Levin. "Targeted delivery was determined to result in a median effective dose that was one thirtieth of that associated with non-targeted delivery, which clearly underscored the potential advantage of the approach."

Levin continues, "There remains a need to target non-hepatic cells specifically and efficiently: a means to achieve this goal could lie in the exploitation of the natural heterogeneity of cell surface receptors."

Dr. Levin has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. Prior to his role at Avidity Biosciences, he held senior drug development roles at miRagen Therapeutics, Ionis Pharmaceuticals and Santaris Pharma. He has played key roles in the development of numerous oligonucleotides, including the first approved antisense NDAs and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Dr. Levin has published over 60 scientific articles and has several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. He received a doctorate in toxicology from the University of Rochester and a bachelor's degree in biology from Muhlenberg College.

About Avidity Biosciences

Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASCs) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is collaborating with partners to discover and develop best-in-class drug candidates against important undrugged therapeutic targets. The company has entered research collaborations with leading biopharma companies and is actively seeking additional partnerships. Avidity has raised $25 million in venture financing from a top-tier group of sophisticated healthcare investors.  More information about Avidity Biosciences can be found on the company's website at www.aviditybiosciences.com.

1  Levin, A, Targeting therapeutic oligonucleotides. N Engl J Med 2016;376: 86-88.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avidity-biosciences-announces-publication-on-targeting-therapeutic-oligonucleotides-by-arthur-a-levin-in-the-new-england-journal-of-medicine-300385825.html


'/>"/>
SOURCE Avidity Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
2. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
3. DuPont Industrial Biosciences to Begin New Research Aimed to Enable Global Access for Protein Medications
4. Roche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences
5. ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
6. ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
7. Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biosciences
8. ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
9. DuPont Industrial Biosciences and MIAVIT Announce Supply Agreement for Biogas Enzymes
10. Agro BioSciences Expands Probiotic Strain Portfolio
11. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):